HLN.L

Haleon plc
Haleon PLC - Completed acquisition of remaining 12% in China JV
27th June 2025, 09:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 7406O
Haleon PLC
27 June 2025
 

Icon Description automatically generated

 

Haleon plc: Completion of acquisition of remaining 12% in China JV

 

27 June 2025: Haleon plc (the "Company" or "Haleon") today announces that it has completed the acquisition announced on 15 April 2025, of the remaining 12% equity interest in Tianjin TSKF Pharmaceutical Co. Ltd ("TSKF"), its OTC joint venture in China for a total consideration of RMB 1,623 million (c. £0.2 billion). As a result, TSKF is now a wholly owned subsidiary of Haleon.

 

China is a key market for Haleon which is underpinned by favourable structural drivers. The acquisition of TSKF which has a long heritage of operational excellence will enable Haleon to drive category growth in one of the fastest growing OTC markets globally. TSKF accounted for c. 40% of Haleon's China revenues in 2024 and manufactures and/or distributes leading brands such as Fenbid, Voltaren and Bactroban. This acquisition will deliver increased strategic, and operational flexibility, and is fully consistent with our capital allocation priorities to drive attractive returns for shareholders and maintain a strong investment grade balance sheet.

 

Enquiries

 

Investors

Media

 

Jo Russell

+44 7787 392441

Zoë Bird

+44 7736 746167

Rakesh Patel     

+44 7552 484646

Victoria Durman

+44 7894 505730

Emma White

+44 7823 523562


 

Email: investor-relations@haleon.com

Email: corporate.media@haleon.com

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

 

For more information, please visit www.haleon.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQFRMPTMTMTMRA]]>
TwitterFacebookLinkedIn